Earlier this week, Bayer announced positive topline results from its Phase III OCEANIC-STROKE trial, showing that asundexian significantly reduced the risk of ischemic stroke without increasing major ...
The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
The FDA has given accelerated approval to Bayer for oral HER2 tyrosine kinase inhibitor sevabertinib as a second-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC), allowing it ...
"We are disappointed that the trial did not show an improvement in progression-free survival in patients with advanced breast cancer," said Dr. Joerg Moeller, Member of the Bayer HealthCare Executive ...
Bayer and United India launch Alivio, an innovative satellite-enabled agri-insurance offering tailored, real-time protection ...
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback